- Brain magnetic resonance imaging software to support dementia diagnosis 1
- in routine clinical practice: a barrier to adoption study in the National 2
- Health Service (NHS) England 3
- 4 Short title: Brain MRI software to support dementia diagnosis in NHS England
- Ludovica Griffanti 1,2,3 *¶, Florence Serres 4¶, Laura Cini 1,3, Jessica Walsh 1,3, Taylor Hanayik 3, Usama 6
- Pervaiz³, Stephen Smith³, Heidi Johansen-Berg^{1,3}, James Rose⁴, Mamta Bajre⁴ 7
- 9 ¹ NIHR Oxford Health Biomedical Research Centre, Oxford, UK
- 10 ² Wellcome Centre for Integrative Neuroimaging, OHBA, Department of Psychiatry, University of
- 11 Oxford, Oxford, UK

8

16

19

- ³ Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical 12
- 13 Neurosciences, University of Oxford, Oxford, UK
- 14 ⁴ Health Innovation Oxford and Thames Valley, Health Innovation Oxford and Thames Valley.
- 15 Magdalen Centre, Oxford Science Park, Oxford, UK
- 17 *Corresponding author
- 18 E-mail: ludovica.griffanti@psych.ox.ac.uk (LG)
- 20 These authors contributed equally to this work

Abstract

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

With the rise in numbers of people living with dementia and new disease modifying therapies entering the market, there is increasing need for brain magnetic resonance imaging (MRI) for diagnosis and safety monitoring. The number of scans that need reporting is expected to rapidly grow. Clinical radiology reports are currently largely qualitative and variable in structure and content. By contrast, research software typically uses automated methods to extract quantitative metrics from brain scans. To better understand the unmet clinical need for brain reporting software for dementia we conducted a barrier to adoption study using the Lean Assessment Process (LAP)methodology. We first assessed the role of brain imaging in the diagnostic pathway for people with suspected dementia in the NHS in England. We then explored the views of (neuro)radiologists, neurologists and psychiatrists on the potential benefits and level of acceptance of software to support brain MRI analysis, using the FMRIB software library (FSL) as a technology exemplar. The main perceived utilities of the proposed software were: increased diagnostic confidence; support for delivery of disease modifying therapies; and the possibility to compare individual results with population norms. In addition to assessment of global atrophy, hippocampal atrophy and white matter hyperintensities, additional user requirements included assessment of microbleeds, segmentation of multiple brain structures, clear information about the control population used for reference, and possibility to compare multiple scans. The main barriers to adoption related to the limited availability of 3T MRI scanners in the UK, integration into the clinical workflow, and the need to demonstrate costeffectiveness. These findings will guide future technical development, clinical validation, and health economic evaluation.

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

In the UK, it is estimated that more than 944,000 people are currently living with dementia, with an associated economic cost forecast at £42 billion to the UK economy in 2024 (1) and predicted to increase to £94 billion by 2040 as the population ages (2) NICE recommends the use of structural imaging, either Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI) in the diagnosis of people with suspected dementia (3). Although CT scanning is widely available, cheaper, and as reliable as MRI in excluding potentially treatable conditions, MRI is more sensitive to detecting subtle changes, to assess vascular pathology, and to aid in differential diagnosis of dementia (4). Subtle brain changes can however be challenging to identify and quantify, as MRI brain scans are currently reviewed visually by a neuroradiologist. Various visual rating scales are available to enable a semi-quantitative assessment, but their impact and inter/intrarater reliability is variable (5), and they require time and expertise (6). As a result, they have not been widely adopted into routine clinical practice, where the information included in imaging reports remains largely qualitative and of variable quality. The 2021 National Audit for Dementia from the Royal College of Psychiatrists reported an increase in MRI scans from 26% of total neuroimaging scans performed in 2019 to 31.8% in 2021 (7), a figure set to increase dramatically in coming years as the population ages and new disease modifying therapies (DMTs) enter the market. Monoclonal antibodies are emerging DMTs for Alzheimer's disease that require brain MR imaging for eligibility assessment and monitoring for amyloid-related imaging abnormalities (8). Extracting accurate quantitative measurements from MRI scans could aid in differential diagnosis for eligibility screening and longitudinal tracking of disease progression, treatment response and safety from side effects. In contrast to the clinic, measures automatically extracted from brain scans to objectively assess atrophy and vascular damage are widely used in dementia research, with a variety of research software tools available (e.g. FSL, FreeSurfer, SPM, AFNI). Additionally, there are multiple commercial products emerging that are regulatory approved for clinical use (9). Despite this, there is limited adoption of dementia neuroimaging tools in clinical settings in UK clinics. Previously reported reasons for (neuro)radiologists not to perform quantitative evaluation in dementia imaging include lack of access to software algorithms and expertise, lack of picture archiving and communication system (PACS) integration, cost, users not comfortable with interpretation and the belief that it would be too timeconsuming or user intensive (6). However, studies suggest that providing a quantitative analysis to clinicians improves interrater variability whilst increasing diagnostic confidence, sensitivity, and accuracy for diagnostic interpretation in dementia (10-12). This barrier to adoption study aimed to assess the current neuroimaging approach used for diagnosing people with suspected dementia in the NHS England. We then explored the views of (neuro)radiologists, neurologists and psychiatrists on the potential benefits and level of acceptance of imaging analysis software in supporting MRI scan analysis. As a technology exemplar for the analysis software, we used the FMRIB software library (FSL) (13). FSL is a software package that includes over 300 tools capable of extracting various metrics from MRI scans, making it suitable for addressing this clinical need. The software is available for free for academic and personal use, and is licensed for commercial use. We asked the stakeholders perception of an FSL-based software with the following characteristics: 1) compatible with MRI scans and integrated in picture archiving and communication system (PACS); 2) automatically provides quantitative measurements of the volume of cerebral structures currently being measured as part of the dementia assessment (mainly global atrophy, hippocampal atrophy, and white matter hyperintensities); 3) displays data against healthy controls matched for age and sex and expressed as percentile of the normative reference population; 4) generates a quantitative report, prepopulated with hospital number sets, age, date of birth, date of scan and

measurements for cerebral structures measured in clinical diagnosis and assessment of dementia.

Material and methods

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

The Health Innovations Oxford and Thames Valley and Wellcome Centre for Integrative Neuroimaging (the developers of FSL) sought to explore how an imaging analysis software tool could support dementia diagnosis in routine NHS clinical practice.

The Lean Assessment Process methodology (14) is used to align evidence generation with available resources at an early stage to explore the unmet clinical needs and the potential barriers to adoption of a new product. The methodology assesses the feasibility of implementing a technology in a care pathway using a preliminary assessment of design, value, and evidence reliability (15). LAP was used to evaluate how the FSL-based software capability and design aligned with the unmet needs in the current dementia diagnosis pathway as well as to identify any potential barrier to its adoption in a clinical setting by engaging with key stakeholders early on in the product development process. Briefly, the dementia diagnosis care pathway was mapped using published guidelines. Ten key stakeholders to interview were identified through both literature review and recommendations. All interviewees were healthcare professionals working in relevant roles within the dementia care pathway across 8 different NHS Trusts in England and included neuroradiologists, general radiologists, FGD-PET radiologists, neurologists and Old Age psychiatrists working in memory clinics. Documents describing the technology were circulated to stakeholders prior to engaging with them. Questionnaires used during the interview contained both qualitative questions on the current landscape and current clinical practices, quantitative product perception questions using a 7-point scale as well as human factor tools adapted from the perceived usefulness questionnaire (16), the stakeholders questionnaire (17) and the net promoter score ((18), which predicts market potential. Qualitative and quantitative data were thematically analysed to build an understanding of the technology acceptability, perceived usefulness and likelihood of its adoption by stakeholders. Moreover, user preferences, stakeholder acceptance, product design and potential barriers of its adoption in the NHS in England were evaluated to further refine the value proposition.

Results

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Views on the current landscape

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

NICE guidelines were largely followed by stakeholders. The current neuroimaging referral pathway is summarised in Fig 1. Fig 1. Current pathway for the diagnosis of people with suspected dementia in the NHS England (NICE guidelines [NG97] Dementia: assessment, management and support for people living with dementia and their carers). Legend: CT: computed tomography, MRI: Magnetic Resonance Imaging, FDG-PET: fluorodeoxyglucose-positron emission tomography-CT, SPECT: single-photon emission CT, CSF: Cerebrospinal fluid, P-tau: phosphorylated-tau, A\(\beta\): \(\beta\)-amyloid, pTau: phosphorylated tau, ESNR: European Society of Neuroradiology. It was recognised by stakeholders that the number of patients referred for neuroimaging is variable across Trusts and clinicians. Most Trusts have a cut-off age to determine whether a patient should be seen by the cognitive neurology team (younger patients) or by an Old Age psychiatrist (older patients). Patients referred to neuroimaging through neurology would all receive an MRI, as the clinicians will be looking for potentially subtle and harder to detect changes in the hippocampus. For psychiatry referrals, CT was predominantly used to rule out alternative causes of cognitive impairment, and is well tolerated in older adults. The level of agreement amongst stakeholders on whether MRI is better than CT in the dementia diagnosis pathway was 88.6%, with clinicians commenting that although the pattern of atrophy or the degree of small vessel disease can be seen on CT, it is "not as good as what you can assess with the MRI". However, access to MR scanners was limited. Establishing the diagnosis lies with the referring clinicians with the support of neuroimaging. In some cases, further imaging assessments are required (Fig 1). However, in practice, this concerns a very small number of patients, judiciously selected, as to not overwhelm the radiology services which was

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

commented upon as being "exceptionally limited and often available off-site in another larger regional hospital". When discussing reporting time, radiologists mentioned that it would take them about 10-15 minutes to review a scan. Neurologists explained that they typically receive the report back from radiology within a few days, whereas for psychiatrists, turnaround times varied across Trusts, ranging from around 2 weeks, up to 6-12 weeks, with up to 3 months from the point of decision to refer to a scan to the person coming back to the clinic. The delay was not necessarily due to radiology, but also to the difficulty of finding an available scanner to perform imaging or a time slot at the memory clinic for reviewing the patient. In the psychiatrists' opinion, the main adverse effect of the delay related to the fact that patients were anxious to receive a diagnosis but that the delay did not really affect patients' management as current treatment options for dementia are limited. Stakeholders also mentioned that reporting was sometimes outsourced to external radiologists to decrease delays when the capacity of Trust's radiology services was limited. Clinicians would provide the radiology department with a short clinical history of the patient, performance on cognitive assessments and the suspected patient's diagnosis on the referral letter. Radiologists commented that they find it particularly helpful when a good clinical history is provided. For example, the presence of "word finding difficulties and aphasia", or of "parkinsonian aspects associated with hallucinations potentially indicative of Lewy bodies dementia" would guide them. Radiologists commented that conversely, referrals with requests such as "please, is there hippocampal atrophy" or "memory loss" without any details were found particularly unhelpful. Most of the radiologists used their own reporting templates that they would manually populate with measurements and scores. Vascular burden and microbleeds were assessed before measuring the pattern of atrophy. The decision to assess specific areas would be guided by the referral letter. Some of the cerebral regions assessed by the radiologists interviewed included medial temporal areas, cingulate region, the dorsal regions, convexity of the palate, frontal lobes, cerebellum, mamillary bodies, corpus

callosum and brain stem. (Neuro)radiologists would sometimes provide quantitative assessments using

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

visual rating scales or a description of severity. Neuroradiologists mentioned reporting MTA scores, ERICA scores, KOEDAM scores, vascular burden as mild, moderate, severe and FAZEKAS scores. Unlike the neurologists, none of the psychiatrists interviewed had access to the scan images, so they would rely purely on the radiologists' reports. All stakeholders emphasised that neuroimaging was part of the diagnostic assessment but not a standalone diagnostic tool. Overall, the content and quality of reports that clinicians received from radiology were hugely variable. Stakeholders agreed on the need for training and better-quality reporting of MRI scans in dementia diagnosis. The level of agreement on the need for software to support the analysis of volumetric MRI scan and provide quantitative data was 80.7%. Perception of the technology Table 1 summarises the answers of the stakeholders to questions about their individual perspective (level of agreement) and the perceived usefulness of the technology. 83.3% of stakeholders stated they would promote the technology in future. When asked about the potential added value, impact on clinical practice and key functionalities of the technology the stakeholders discussed several aspects. Table 1. Stakeholder's average level of agreement and perceived usefulness of the proposed analysis software based on FSL. **Individual perspective - level of agreement** 1 MRI is better than CT in the diagnosis pathway of people with suspected dementia. 88.6% 2 There is an unmet need for an analysis software to support the analysis of MRI scans and to 80.7% provide quantitative data. 3 Quantitative data in MRI reporting can increase diagnostic specificity, accuracy and 88.6%

confidence while decreasing inter-rater variability.

4	Quantitative data from MRI can help with differential diagnosis which in turn, can help	76.4%
	better inform patient's care needs.	
5	Quantitative data from MRI can be useful with early diagnosis in a subpopulation of	81.4%
	patients with suspected dementia.	
6	A software like the one proposed, that automatically produces volumetric MRI	77.1%
	measurements and generates a prepopulated report, can save radiologists/clinicians time and	
	improve workflow.	
7	In view of the research effort to develop drugs for dementia, quantitative data from MRI	81.4%
	would be useful in clinical practice when disease-modifying drugs become available.	
8	Do you agree that there are potential barriers to the adoption of the proposed software for	78.6%
	clinical use?	
Perceived usefulness		
1	Improve quality of work	75.0%
2	Give greater control of work	63.4%
3	Enable to accomplish tasks more quickly	57.1%
4	Support critical aspects of the job	72.3%
5	Increase productivity	59.8%
6	Improve job performance	73.2%
7	Allow to accomplish more work	58.9%
8	Enhance effectiveness on the job	73.2%
9	Make job easier to do	66.1%
10	Overall, this product is useful	80.4%

Increased confidence. Both radiologists and clinicians mentioned increased confidence in diagnosis as the main added value. The level of agreement amongst stakeholders on the capability of quantitative MRI reports to increase diagnostic specificity, accuracy and confidence while decreasing inter-rater variability was 88.6%. Having quantitative data would give them greater confidence in the MRI findings and potentially reduce the need for further FDG-PET scans, which are more expensive and with less capacity. However, some neuroradiologists raised concerns about people with little experience of

185

186

187

188

189

190

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

dementia imaging using the sort of software that might give a sense of "false reassurance to a general radiologist". "Then you can very, very quickly say: okay the pattern in this convincingly matches the clinical input." Nothing else to be said. You move on. So it would be straight forward for the patient, straight forward, for the clinician, straight forward for radiologist. So you have less patients in the limbo they are until you reach a diagnosis, which sometimes is very time consuming."- Consultant neuroradiologist "I think a neuroradiologist would know what is going on but if you don't have a neuro background, and it is just purely imaging, that is a different conversation". - Consultant neuroradiologist Support delivery of disease modifying therapies (DMTs). The level of agreement on whether quantitative MRI would be useful to clinicians when DMTs become available was 81.4%. Some stakeholders believed MRI in this pathway will be used to look for dementia drugs contraindications because of the risk of bleeds associated with their use. Others felt that MRI will be used to monitor the effects of these drugs on disease progression and in that context, quantitative MRI will provide valuable data. However, stakeholders also commented that the whole dementia diagnosis pathway is likely to change with the arrival of dementia-modifying drugs and that eligibility criteria for these expensive treatments will be based on fluid biomarkers such as serum amyloid levels or amyloid-PET rather than MRI. In some stakeholders' views, the future of MRI in the dementia pathway will not be for diagnostic purposes as fluid biomarkers will likely have higher predictive value, lower cost and higher accessibility than MRI. Instead, they see MRI being used for safety monitoring and for determining which treatments patients should receive. "I would say vital. So when we get to dementia modifying drugs, there will be a pathway. I think the pathway will involve both neuroimaging, potentially blood biomarkers for negatives and then only in the people where you've really done everything to rule out other causes, do you do the lumbar puncture." - Consultant psychiatrist

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

"...[diagnostic] criteria is going to be amyloid status rather than any other parameters, so it would be amyloid-PET or hopefully serum levels of amyloid and other relevant actors" - Consultant psychiatrist "...the future of MR imaging in dementia diagnosis is not going to be diagnostic. It's going to be safety for treatment ... The diagnosis will be done in a different way." - Consultant neurologist Comparison with a control population. One of the main perceived benefits of such a software tool was that it would provide comparison of the patient's measurement with those of a normative population matched for age and sex. All stakeholders commented that this information would be very valuable both in a younger population of patients where the volume of cerebral structures such as the parietal cortex is highly variable, as well as in the older population where the rate of atrophy varies significantly between individuals and does not necessarily correlate with cognitive impairments. However, stakeholders were keen to be provided with information on the composition of the control population used to display the results (and train the AI if applicable). Questions asked pertained to how many control scans were going to be used (to judge the variance of the results), where the control population came from (to make sure it is representative of the population where the tool is being deployed), and if an amyloid scan has been performed on these healthy individuals (to check whether they could be in a pre-dementia state). Uncertainty around the control population was also the main reason for loss of confidence in commercially available software that had been tried by some stakeholders. Assessment of microbleeds and vascular pathology. Microbleeds were seen as extremely important to consider. Although their assessment is not part of the current dementia diagnosis, stakeholders felt that they will need to be measured more accurately by neuroradiologists when new dementia drugs are available. Quantification of microbleeds and vascular change would inform on what the bleeding risk would be for disease management and informing treatment. "At the moment, we don't use and I don't need it, but I can see that a rapid automated assessment to determine the risk of bleeds and that would become of particular value when we come to the treatment for the amyloid which is not very far away." - Consultant neuroradiologist

Other added values of the technology for stakeholders were the possibility to detect subtle changes, save time saving, and differentiate age related changes from pathological changes. Other key functionalities mentioned to be added to the software were comparison of multiple scans, and segmentation of multiple brain structures to assess atrophy patterns and other abnormalities.

Barriers to adoption

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Stakeholders recognised the likelihood of barriers to the adoption of a software tool like the proposed one in the clinical setting, with 78.6% agreement to the question: "Do you agree that there are potential barriers to the adoption of the proposed software for clinical use?" Key barriers to adoption of such a software tool were the limited access to MRI scanners, in particular 3 Tesla, in NHS services and therefore CT is widely relied on in the dementia care pathway. The psychiatrists interviewed estimated the ratio to be 2/3 CT and 1/3 MR in one trust and 95% of CT in the other. The demand for MRI scans for eligibility screening and safety monitoring in the dementia care pathway will increase in the coming years when DMTs come to market. However, in the UK there are currently 8.6 MRI scanners per million people compared to 38 and 35.3 in the US and Germany respectively (19). "MRI access is an issue. We are not really encouraged to ask for MRI scans. So if I asked for CT scan, they're pretty much will always say yes; If I ask for an MRI scan, they'll triage it much more carefully."-Consultant Psychiatrist "Because of various things, as we've discussed, about capacity, availability, some patients can't have an MRI. I think in an ideal world, you would want everyone to have an MRI, but we don't live in an ideal world."- Head and Neck Consultant Radiologist Additional barriers identified by stakeholders were related to integration in the clinical workflow (IT and time requirements); structural issues within the NHS making it hard for innovations to be adopted; potential issues with information governance; managers' attitudes towards innovation; and the cost of the technology. Stakeholders explained that to introduce an innovation into the department, one needs to write a business case to demonstrate that the innovation will be cost-effective. For example, "to demonstrate that saving time on reporting scan would result in xx extra scan reported, equating to 'x' amount of savings". This business case would therefore be highly dependent on the number of dementia scans processed in the radiology department. If dementia scans are not the bulk of their activity, radiologists will have to demonstrate that the software could be used for imaging of other pathologies, such as multiple sclerosis. However, stakeholders also thought that although cost would be an issue, they were confident that there were ways around it, for example using champions to promote the analysis software.

Discussion

The current study aimed at exploring the perceived usefulness and level of acceptance of a brain imaging software tool, using FSL as a technology exemplar for the analysis software, in providing quantitative reporting of MRI scans in the dementia diagnosis pathway. To gain a broad view of potential barriers to adoption in clinical practice in NHS England, we interviewed stakeholders who worked in 8 different Trusts across England in relevant roles in the dementia pathway.

Although imaging is an integral part of the dementia pathway in most cases, the choice of CT vs MRI is made mainly based on the referring service (CT for psychiatry, MRI for neurology) and access to MRI scanners. Reporting time is heterogeneous for psychiatry and neurology, and the content of reports is variable. Reports usually contain common elements, but the level of detail provided, as well as the use of visual rating scales is not consistent. Despite clinicians and radiologists agreeing on the usefulness of structured reports, there was no consensus on a common template. This is in line with what has been recently reported by the European Society of Radiology: while in many countries national radiological societies have launched initiatives to further promote structured reporting, cross-institutional applications of report templates (e.g., for registries or research) and incentives for usage of structured reporting (monetary or structural) are lacking (20). In addition, the specificity in the referral question, the specialty of the radiologist/neuroradiologist, and specialty of the referring clinician seem

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

to contribute to the heterogeneity in content as well as to the level of trust in the report. Importantly, while neurologists have access to the images and often personally review them alongside the radiology report, psychiatrists typically only have access to the report and not the images. In this context, stakeholders agreed that there was a need for software to provide volumetric quantification of brain MRI and for better reporting in the dementia diagnosis pathway. With the shortage of radiology workforce (29% in 2022 (21)) and the predicted increased number of referrals for dementia diagnosis scans, the proposed software was seen as a useful radiology support tool for analysing brain scans. For radiologists, although the software was perceived as not saving time per se, they would expect it to increase their diagnostic confidence by allowing patients to be compared to normative data. For clinicians, the creation of a structured report collating all the information needed to make a diagnosis was also seen as helpful. More importantly, it could reduce the variability between reporters and decrease the subjectivity of the report, a point seen as important by clinicians in the context of shortage of neuroradiologists. If the proposed FSL-based software was coupled with additional features such as measuring other cerebral structures, comparing scans and microbleeds measurement, this software could serve several purposes within the dementia pathway: as a diagnostic tool to better identify the subtype of dementia and reduce the need for further investigation; as a monitoring tool to measure subtle changes and evaluate disease progression or the effect of disease-modifying treatments; and/or as a tool to identify risk of bleeding, particularly relevant in view of the safety monitoring required for dementia drugs soon to be available. When discussing their confidence in the outputs of the software, stakeholders explained that they would have to be provided with information on the software's sensitivity and specificity. Information on the control population used would be useful to reassure users that it is representative of the local population both in its diversity and across all ages. Stakeholders also mentioned the important balance between the software increasing confidence and the risk of creating a "false sense of reassurance" that the

measurements are adequate if they lack the knowledge to quality-control the findings of the software.

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

One of the main barriers to adoption of such software was the limited access to MRI scanners, and therefore the fact that CT is widely relied on in the dementia care pathway. Other barriers mentioned by all stakeholders were the cost and the need to demonstrate that the software would be a cost-effective tool for brain reporting. Stakeholders were unsure whether using quantitative MRI could save them time or reduce the need for further investigations. Some stakeholders were of the view that the role of quantitative MRI in the future dementia diagnosis pathway would only be to assess the risk of bleeds. while biofluid measurements will probably become the mainstream diagnostic biomarkers for early dementia. Showing that the software could be useful in other pathways, and finding champions to promote it, were proposed by stakeholders as potential solutions to convince NHS managers to acquire it. While covering a broad complement of stakeholders in relevant roles in the dementia diagnosis pathway, across 8 different NHS trusts, the stakeholder sample size was small (n=10) which is a limitation of this study. Altogether, this barrier to adoption study using LAP methodology reported that stakeholders were very positive about the potential usefulness of brain analysis software tool in the dementia diagnosis pathway, as reflected by the overall usefulness score of 80.4%, a score even greater for radiologists as primary users of the software. This study highlighted several future directions towards the adoption of brain imaging software to support dementia diagnosis in the NHS England. Regarding the software technical requirements, specific measures (microbleeds, segmentation of multiple structures) and functionalities (representative control population, comparison of scans over time) were mentioned as important to include to meet clinical needs. These improvements should be supported with technical validation studies to improve confidence in the software. A clinical evaluation study involving clinical end-users would test the value of the software compared to a standard reading. This could include measuring the reporting time and accuracy, assessing confidence in diagnosis, as well as gathering feedback around the usability and acceptability of the software. An integration test in a clinical setting would enable assessing the impact

343

344

345

346

347

of the software in the clinical workflow. Joint clinical-research facilities like the Oxford Brain Health Clinic (22) provide an ideal translational interface to test the software on data from real-world clinical populations in a research setting, while building evidence for further adoption. Finally, a real-world health economic evaluation will be required to determine the cost-effectiveness and to capture the clinical effectiveness as well as gathering further clinical evidence.

References

- 349 1. Carnall Farrar AsS. The economic impact of dementia [Available from:
- 350 https://www.carnallfarrar.com/wp-content/uploads/2024/06/The-economic-impact-of-dementia-
- 351 CF.pdf.


- 352 2. Wittenberg R, Hu B, Barraza-Araiza L, Rehill A. Projections of older people living with
- 353 dementia and costs of dementia care in the United Kingdom, 2019–2040. Care Policy and Evaluation
- 354 Centre Working Paper 5, London School of Economics and Political Science; 2019.
- 355 3. NICE. Dementia: assessment, management and support for people living with dementia and
- 356 their carers. NICE guideline [NG97]2018.
- 357 4. van Straaten EC, Scheltens P, Barkhof F. MRI and CT in the diagnosis of vascular dementia.
- 358 J Neurol Sci. 2004;226(1-2):9-12.
- 359 Harper L, Barkhof F, Fox NC, Schott JM. Using visual rating to diagnose dementia: a critical
- 360 evaluation of MRI atrophy scales. Journal of neurology, neurosurgery, and psychiatry.
- 361 2015;86(11):1225-33.
- 362 6. Vernooij MW, Pizzini FB, Schmidt R, Smits M, Yousry TA, Bargallo N, et al. Dementia
- 363 imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR
- 364 working group. Neuroradiology. 2019;61(6):633-42.
- 365 7. Psychiatrists RCo. National Audit of Dementia: Memory Assessment Services Spotlight
- 366 Audit 2021. 2022.
- 367 Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR, Jr., Poussaint TY, et al.
- 368 Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection
- 369 and Reporting Recommendations for Clinical Practice. AJNR American journal of neuroradiology.
- 370 2022;43(9):E19-E35.
- 371 Pemberton HG, Zaki LAM, Goodkin O, Das RK, Steketee RME, Barkhof F, et al. Technical 9.
- 372 and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a
- 373 systematic review. Neuroradiology. 2021;63(11):1773-89.

- 374 10. Pemberton HG, Goodkin O, Prados F, Das RK, Vos SB, Moggridge J, et al. Automated
- 375 quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater,
- 376 clinical accuracy study. Eur Radiol. 2021.
- 377 Bosco P, Redolfi A, Bocchetta M, Ferrari C, Mega A, Galluzzi S, et al. The impact of
- 378 automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's
- 379 disease: A European Alzheimer's Disease Consortium study. Alzheimer's & dementia: the journal of
- 380 the Alzheimer's Association. 2017;13(9):1013-23.
- 381 12. Goodkin O, Pemberton H, Vos SB, Prados F, Sudre CH, Moggridge J, et al. The quantitative
- 382 neuroradiology initiative framework: application to dementia. Br J Radiol. 2019;92(1101):20190365.
- 383 13. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. FSL. NeuroImage.
- 384 2012;62(2):782-90.
- 385 Baire MT, A; Stainthorpe, A; Hart, J. Results from an Early Economic Evaluation of the use
- 386 of A Novel Point of Care Device for Diagnosis of Suspected Acute Coronary Syndrome Patient
- 387 Within an Emergency Department in the National Health Service in England. Cardiology and
- 388 Cardiovascular Medicine. 2021;5:623-37.
- 389 15. Baire M, Moawad M, Shumbayawonda E, Carolan JE, Hart J, Culver E, et al. LiverMultiScan
- 390 as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in
- 391 England: an economic evaluation. BMJ Open. 2022;12(9):e058999.
- 392 16. Davis FD. User Acceptance of Information Technology: System Characteristics, User
- 393 Perceptions and Behavioral Impacts. Int J Man Mach Stud. 1993;38:475-87.
- 394 17. World Health Organization. Regional Office for the Western P. Health service planning and
- 395 policy-making: a toolkit for nurses and midwives - Module 2: Stakeholder analysis and networks.
- 396 Manila: WHO Regional Office for the Western Pacific; 2005.
- 397 Reichheld FF. The one number you need to grow. Harv Bus Rev. 2003;81(12):46-54, 124. 18.
- 398 OECD. Number of magnetic resonance imaging (MRI) units in selected countries as of 2021 19.
- 399 (per million population). Statista Inc.; 2023.
- 400 European Society of R. ESR paper on structured reporting in radiology-update 2023. Insights 20.
- 401 Imaging. 2023;14(1):199.

- 402 21. Radiologists TRCo. Clinical Radiology Workforce Census 2022. 2023.
- 403 22. O'Donoghue MC, Blane J, Gillis G, Mitchell R, Lindsay K, Semple J, et al. Oxford brain
- 404 health clinic: protocol and research database. BMJ Open. 2023;13(8):e067808.

Current pathway for the diagnosis of people living with dementia

Referral received by General Practitioner. Reversible causes of cognitive decline (including delirium, depression, sensory impairment [such as sight or hearing loss] or cognitive impairment from medicines associated with increased anticholinergic burden) have been investigated **and** dementia is still suspected



Only consider further tests if it would help to diagnose a dementia subtype and knowing more about the dementia subtype would change management

